NASDAQ : MSLE

Satellos Bioscience Inc. — Company profile

Healthcare · Biotechnology · Canada

Last price 6.815 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 145.77M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Details

NameSatellos Bioscience Inc.
SectorHealthcare
IndustryBiotechnology
Employees21
Founded2018
CeoFrancis Gleeson
CountryCanada
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinCA80401L8033
Cusip80401L803
Cik1421642
Sic2834

Key executives

NameTitle
Francis Gleeson B.B.A. M.B.ACo-Founder, Chief Executive Officer, President and Director
Elizabeth Williams C.A., CPAChief Financial Officer and Corporate Secretary
Dr. Philip Lambert M.A., Ph.D.Chief Scientific Officer
Dr. Wildon Farwell M.D., M.P.H.Chief Medical Officer
Dr. Michael A. Rudnicki Ph.D.Co-Founder and Chief Discovery Officer
J. Robert Hall CFASenior Vice President of Finance and Administration
Dr. Ryan Mitchell Ph.D.Senior Vice President and Head of Corporate Development
Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A.Strategic Advisor
Warren Whitehead C.M.A., CPAHead of Corporate Strategy
Desiree ChanChief of Staff

Contact

AddressRoyal Bank Plaza, Suite 2800, Toronto, ON M5J 2J1, Canada
Websitehttps://satellos.com